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Background. Patients with moderate-to-severe psoriasis are often treated with systemic immunosuppressant agents that decrease
immune system function. For the elderly, these medications are often problematic due to their already immunosuppressed state
and comorbidities. However, there are few studies examining the eﬀects of these medications on the elderly age group. Therefore,
there is often discomfort among dermatologists treating elderly patients with psoriasis in utilizing systemic agents, frequently
resulting in inadequate treatment. Objective. We review the safety proﬁles of systemic treatments often used to treat psoriasis
and their possible adverse risks to the geriatric population. Methods. We conducted a search of PubMed’s Medline database of
articles published from 2000 to 2011, which resulted in 14 articles. Conclusion. Treating geriatric patients with moderate-to-severe
psoriasis remains a challenge due to immunosenescence and comorbidities. More studies focusing on psoriasis treatment safety in
the geriatric population are needed.
1.Introduction
Psoriasis is a chronic, debilitating skin disease that aﬀects ap-
proximately2.6%ofthegeneralpopulation[1].Patientswith
psoriasis develop erythematous, scaly, and well-demarcated
plaques that are often pruritic and can be painful. Due to
its chronic nature, psoriasis increasingly aﬀects the geriatric
population.AUSstudyin1991reportedthatthehighestrate
of psoriasis, 113/100,000 population, occurred in the 60- to
69-year age group [2]. With the growing geriatric population
expected to compose 25% of the US population by 2020, the
prevalence of psoriasis is also expected to rise [3].
There are two key challenges for treating an older patient
with psoriasis. The ﬁrst key challenge involves the already
immunosuppressed state of the elderly, also known as im-
munosenescence.Immunosenescenceisatermthatdescribes
the immunosuppressed state of the elderly due to natural
aging [4]. This is due to a marked decrease in T-cell func-
tion with aging as well as other age-related changes in
innate immunity [5]. As a result of immunosenescence, the
elderly are at a higher risk than younger age groups to
develop cancer, infectious disease, neurodegenerative dis-
ease, and chronic inﬂammatory diseases such as atheroscle-
rosis. However, immunosuppressive therapies are consid-
ered the mainstay for managing psoriasis and make up
the majority of systemic psoriasis treatments. The second
key problem in treating geriatric patients with psoriasis is
that the elderly often have comorbid illnesses that can be
worsened by adverse eﬀects of psoriasis therapies. Older
patients frequently have one or more comorbid illnesses that
include cardiovasculardisease, kidney insuﬃciency, liver dis-
ease, dementia and cognitive disability, diabetes, metabolic
syndrome, and obesity, to name a few.
There are few studies examining the eﬀects of these sys-
temic medications on the elderly age group. Therefore, there
is often discomfort among dermatologists treating elderly
patients with psoriasis. Herein, we review the safety proﬁle
of systemic agents often prescribed for psoriasis and their
possible adverse eﬀects on the geriatric population.2 Dermatology Research and Practice
2. Methods
We conducted a search of PubMed’s Medline database of
articlespublishedfrom2000to2011toincludeonlythemost
recent literature. Articles containing the key words geriatric
population, elderly, immunosuppression, and psoriasis were
reviewed. In addition, diﬀerent treatment modalities includ-
ing biologic agents, acitretin, cyclosporine, and methotrexate
were combined with the key words geriatric and elderly.T h e
search was limited to articles in English. The search initially
resulted in 338 articles. Article abstracts were reviewed for
relevance to the subject matter. We examined reference
lists to identify any missing articles. Articles included in
the review speciﬁcally discussed the use of systemic agents
in the elderly, the safety proﬁles of the systemic agents,
and/or adverse risks to the elderly. Articles excluded from the
review included studies and other review articles that did not
speciﬁcally discuss the use of systemic agents in the elderly
population or the safety proﬁles of systemic agents.
3. Results
After a thorough assessment of articles in the Medline data-
base, 14 relevant articles were included in this review. 4 Food
and Drug Administration (FDA) package labels were also
incorporated in the review.
Systemic immunosuppressive therapies for psoriasis in-
clude biologic agents such as adalimumab, inﬂiximab, etan-
ercept (tumor necrosis factor (TNF) α blockers), ustekin-
umab (interleukin 12/23 monoclonal antibody), and alefa-
cept(T-cellinhibitor). Inthetreatmentofpsoriasis, thereare
also options of nonbiologic immunosuppressive agents that
include cyclosporine and methotrexate and a nonimmuno-
suppressive systemic agent, acitretin.
3.1. Systemic Agents and Immunosuppression. Immunosup-
pression is a concern when using biologic agents. Adali-
mumab and inﬂiximab have been demonstrated to increase
tuberculosis risk [6], histoplasmosis [7], and other granulo-
matous diseases [8]a sw e l la sh e r p e sz o s t e r[ 9]a n dm a l i g -
nancy [10]. Ustekinumab has been implicated to increase
cardiovascular risk due to earlier phase II research ﬁndings,
although later data did not demonstrate such risks. In phase
II trials of ustekinumab, more adverse cardiovascular events
(MACE) such as heart attack, stroke, and sudden cardiac
deathwerefoundintheexperimentalgroupthantheplacebo
group in psoriasis trials [11]. However, this has not been
shown in phase III trials or four-year long-term data.
There have been some studies that compare the use
of immunosuppressive agents between older and younger
cohorts with rheumatologic diseases, such as rheumatoid
arthritis, psoriatic arthritis, and ankylosing spondylitis. Safe-
ty data extrapolated from the literature of rheumatologic
diseases raises concern for using these agents in the elderly.
A study of all anti-TNF α agents in patients with rheumatoid
arthritis showed that there was a signiﬁcant overall risk of
increased serious infections of the elderly over age 65 com-
pared to younger cohorts [12]. The study compared the risk
of serious infections in 11,798 anti-TNF treated patients and
3,598 nonbiologic treated patients from the British Society
for Rheumatology Biologics Registry [12]. The consequence
forthisstudyisthatphysiciansarelesslikelytoprescribebio-
logic agents to the elderly because of their already decreased
immune function. However, one study demonstrated long-
term safety of etanercept on elderly patients with rheumatic
diseases. The study measured serious adverse events, infec-
tious events, medically important infections, and deaths
in 597 geriatric patients over the age of 65 and 3,296
nongeriatric patients with rheumatic diseases [13]. It found
no statistically signiﬁcant diﬀerence in safety between elderly
and younger age groups [13].
A study by Militello et al. compared the eﬃcacy and
tolerability of etanercept for the treatment of psoriasis in
elderly and nonelderly populations. The study found that
there were no signiﬁcant diﬀerences in the quality of life, as
measured by the Dermatology Life Quality Index (DLQI),
and in eﬃcacy, as measured by Psoriasis Area and Severity
Index (PASI) [14]. Although it showed that there was a
signiﬁcant increase in serious adverse events in the elderly
group, these events were reported as not associated with
treatmentwithetanercept.Inaddition,injectionsitereaction
events were not signiﬁcantly diﬀerent between the older and
younger age groups [14].
Furthermore,FDAlabelingforbiologicagentsraisescon-
cerns for safety in the elderly. According to the FDA package
insert for adalimumab (Humira), the frequency of serious
infections and malignancies was higher in the elderly than
in younger cohorts [15]. The package inserts for inﬂiximab
(Remicade), ustekinumab (Stelara), and etanercept (Enbrel),
however, reported no overall diﬀerence in safety in the
geriatric population compared to younger age groups [16–
18]. The package inserts for inﬂiximab, ustekinumab, and
etanercept also warn that because the risk of infection is
higher in the elderly in general, caution should be used when
administering these medications in the geriatric population.
3.2. Systemic Agents and Comorbidities. One biologic agent,
ustekinumab, has been implicated in possible increased risk
to cardiovascular health. The immunosuppressive agent,
cyclosporine has not been studied in elderly with psoriasis
speciﬁcally but has the potential to cause damage to sev-
eral organ systems. Elderly patients often have decreased
baseline renal impairment due to aging. Cyclosporine can
worsen renal insuﬃciency and can raise the creatinine
level. Age-related decline in renal clearance of cyclosporine
has been shown in geriatric kidney transplant recipients
[19]. Cyclosporine also can increase blood pressure, which
is carefully monitored for the side eﬀect of hypertension at
each clinic visit. Cyclosporine cannot be used in patients
with abnormal baseline serum creatinine and glomerular
ﬁltration rate and is used with caution in the elderly [20].
Methotrexate is another eﬀective nonbiologic immuno-
suppressive psoriasis treatment that can adversely aﬀect
multiple organ systems. A major concern for possible harm
of methotrexate is to the hepatic system, as methotrexate
has been implicated in hepatic ﬁbrosis and cirrhosis. Elderly
patients are at increased risk for hepatotoxicity because ofDermatology Research and Practice 3
anincreasedtendencyforelevatedtriglycerides,elevatedliver
function tests, and obesity that are often found in the aging
population and are associated with methotrexate-related
hepatic ﬁbrosis [20]. A liver biopsy is required with long-
term use of methotrexate, a risk for the elderly that may out-
weigh the beneﬁts of preventing liver damage. Methotrexate
renal clearance is inversely proportional to the patient’s age
and, therefore, increases renal insuﬃciency in the elderly,
making this agent more problematic [21]. Myelosuppression
is another rare side eﬀect occurring in the geriatric pop-
ulation associated with this medication [22]. Patients on
methotrexate with comorbid diabetes mellitus are at greater
risk for cirrhosis and severe liver ﬁbrosis [23].
One systemic agent for psoriasis that is not an immuno-
suppressant is acitretin. It is also an eﬀective psoriasis treat-
ment. Though not an immunosuppressant, it also has the
potentialtocauseharmtoseveralorgansystems,raisingcon-
cern for use in the elderly. Acitretin is a second-generation
retinoid that may increase cardiovascular risk. It can cause
hypertriglyceridemia[20,23].Inaddition,itadverselyaﬀects
the integumentary system by increasing dryness of the skin
and mucosal membranes. This exacerbates xerosis that is
a l r e a d ym o r ec o m m o ni nt h i sa g eg r o u p .
Another issue that arises when treating the geriatric
population is polypharmacy and consequent drug interac-
tions. Old age is associated with decreased excretory kidney
capacity, causing higher risk for adverse drug reactions and
interactions especially with multidrug regimens commonly
seen in this population. Methotrexate, for example, has
a potentially fatal drug interaction with trimethoprim, a
common mainstream antibiotic [20].
4. Discussion
Based on studies and known risks of systemic medications,
physicians and patients both face challenges for determining
how to adequately treat psoriasis and avoiding increased
harm that may outweigh the beneﬁts of treatment. Further
research is needed to develop and make possible medications
with decreased risk for cancer, infection, and worsening
comorbidities. Extensive studies should be carried out to
understand the eﬀects of these systemic agents speciﬁcally
on the geriatric psoriasis population. In addition to research,
the management of elderly patients with psoriasis can be
improved by educational programs. Currently, many der-
matologists are not comfortable with treating the elderly
psoriasis patient with these agents and are inadequately
treating them by using topical therapies alone. However, a
consensus meeting of geriatric dermatology experts should
be organized to develop speciﬁc guidelines for dermatol-
ogists and other physicians about optional treatments for
psoriasis in the elderly.
For now, however, without speciﬁc guidelines and ade-
quate research into this topic, a more careful management
of the elderly patient with psoriasis is needed. A cautious
approach can be taken with a thorough history and physical
examination. Included in the history, physicians should
document all current and past medications as well as drug
allergies and side eﬀects of medications to prevent adverse
drug interactions and reactions. A careful history of immu-
nosuppressive use is needed to ensure that the cumulative
dose of the agent is not beyond the standard recommended
by the FDA to cause toxicity to an organ system. The physical
examination should be a thorough head-to-toe examination,
with particular emphasis on the cardiovascular, respiratory,
and musculoskeletal systems. Vital signs should be taken
twice, in particular to ensure that the patient does not
have hypertension if the physician is planning to prescribe
cyclosporine. Extensive laboratory workup is needed to
evaluate for hepatic decline (liver function tests), renal
insuﬃciency (creatinine and possibly glomerular ﬁltration
rate), hyperlipidemia, electrolytes, low white blood cell
count, low platelets, and low red blood cell count that
would be considered contraindications for certain systemic
therapies.
When prescribing medications, it is important to start
with a small dose and then titrate up to higher doses to
a deﬁned therapeutic response. Physicians should make an
eﬀort to reduce the number of medications the patient needs
to take and should regularly check for possible interactions
and adverse eﬀects.
For a healthy, active elderly patient with no or limited
comorbidities, etanercept can be used for psoriasis treatment
with careful monitoring. Etanercept has been the only sys-
temic biologic agent that has shown to be safe in the
elderly, possibly due to its lower immunosuppressive ability
compared to other biologic agents. However, a larger sample
size of psoriasis-speciﬁc elderly patients is needed to further
conﬁrm its safety.
If an elderly patient has multiple comorbidities and risk
factors that make him/her a poor candidate for an oral
or injectable systemic agent, phototherapy and strict com-
pliance to topical therapies are recommended. Ultraviolet
B (UVB) and psoralen ultraviolet A (PUVA) phototherapy
are noninvasive with minimal side eﬀects limited to mild
erythema, burning, and blistering. However, the patient may
be challenged by the phototherapy box that requires him or
her to be able to stand in the unit without mobile support
or guard rails to maintain balance. In addition, some geri-
atric patients lack transportation or have arthritis or hip
impairment that prevent them from being able to move
themselves to a dermatology clinic for phototherapy. Drug-
induced photosensitivity can also occur if a careful drug
history is not taken.
5. Conclusion
There is heightened concern about the use of systemic pso-
riasis medications for the elderly. These medications can be
very eﬀective and are considered the mainstay of treatment
for moderate-to-sever psoriasis. Virtually all new agents
being developed to treat psoriasis are immunosuppressants.
However, studies have demonstrated increased risk involved
in treating elderly patients with these therapies due to
increased comorbidities and immunosenescence. Therefore,
many elderly patients are not adequately treated and suﬀer4 Dermatology Research and Practice
the physical and psychological eﬀects of psoriasis. These
include discomfortand pain frompsoriatic plaquesaswell as
depression, anxiety, and stigma from the public because the
plaques are often disﬁguring. Physicians should remember
thatthegoalsoftreatingpsoriasisintheelderlyaretoachieve
clinical control of the skin disease, improve quality of life of
the patient, and administer safe and tolerable treatments. It
is important for physicians and health care workers serving
this patient population to understand the risks associated
with systemic agents, initiate and engage in research focusing
on the elderly to study these agents and also to investigate
new psoriasis therapies, and be willing to treat these patients
thoroughly and cautiously so that they are able to obtain
adequate treatment to decrease suﬀering of generalized
psoriasis.
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